Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Treatment with 1 alpha-OHD3 supplemented with calcium will possibly unveil symptoms of spinal pain (8/10) and increase physical activity (7/10) in patients suffering from osteoporosis. An increase in trabecular bone (8/10) as well as a decrease in bone resorption (9/10) accompanied by measured increased bone mineral (6/10) has been observed. Some patients did not show any response to this kind of treatment.
D000368:Aged; D001842:Bone and Bones / Q000032:analysis / Q000473:pathology*; D002112:Calcifediol / Q000097:blood; D002118:Calcium / Q000032:analysis / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006934:Hypercalcemia / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D008903:Minerals / Q000032:analysis*; D010018:Osteomalacia / Q000150:complications; D010024:Osteoporosis / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D006887:Hydroxycholecalciferols; D008903:Minerals; D002112:Calcifediol; D002118:Calcium; C008088:alfacalcidol